Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20003794 | 0.85 | FDPS (0.36) | MAPK14MAPK10HRH4FDPSHTR7 | |
| SCHEMBL3555705 | 0.79 | HTR7 (0.59) | MAPK14HTR7 | |
| SCHEMBL24815412 | 0.78 | HRH4 (0.44) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL29851369 | 0.78 | FDPS (0.59) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL828257 | 0.78 | FDPS (0.59) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL2730632 | 0.77 | — | — | |
| SCHEMBL15102638 | 0.76 | MAPK14 (0.42) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL12356613 | 0.76 | MAPK14 (0.42) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL17131640 | 0.76 | MAPK14 (0.52) | MAPK14MAPK10HRH4 | |
| SCHEMBL23066110 | 0.76 | MAPK14 (0.47) | MAPK14MAPK10HRH4FDPSTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| CN-110573509-A | MLKL inhibitors | 北京生命科学研究所 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018157800-A1 | MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-07 | — | — | WO | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | MAPK14 633/4885MAPK10 1189/4885HRH4 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.